

Real-world efficacy and safety of universal 8-week glecaprevir/pibrentasvir for treatment-naïve patients from a nationwide HCV registry in Taiwan

Chun-Chi Yang^{1*}, Chung-Feng Huang^{2,3*}, Te-Sheng Chang^{4,5}, Ching-Chu Lo⁶,
Chao-Hung Hung⁷, Chien-Wei Huang⁸, Lee-Won Chong^{9,10}, Pin-Nan Cheng¹¹,
Ming-Lun Yeh^{2,12}, Cheng-Yuan Peng^{13,14}, Chien-Yu Cheng¹⁵, Jee-Fu Huang^{2,12,16},
Ming-Jong Bair^{17,18}, Chih-Lang Lin¹⁹, Chi-Chieh Yang²⁰, Szu-Jen Wang²¹, Tsai-Yuan Hsieh²², Tzong-Hsi Lee²³, Pei-Lun Lee²⁴, Wen-Chih Wu²⁵,
Chih-Lin Lin²⁶, Wei-Wen Su²⁷, Sheng-Shun Yang²⁸, Chia-Chi Wang²⁹, Jui-Ting Hu³⁰, Lein-Ray Mo³¹, Chun-Ting Chen^{22,32}, Yi-Hsiang Huang^{33,34},
Chun-Chao Chang^{35,36}, Chia-Sheng Huang³⁷, Guei-Ying Chen³⁸, Chien-Neng Kao³⁹, Chi-Ming Tai^{40,41}, Chun-Jen Liu⁴², Mei-Hsuan Lee⁴³, Hsing-Tao
Kuo¹, Pei-Chien Tsai^{2,12}, Chia-Yen Dai^{2,12}, Jia-Horng Kao⁴², Han-Chieh Lin^{33,34}, Wang-Long Chuang², Kuo-Chih Tseng^{44,45}, Chi-Yi Chen^{46**},
Ming-Lung Yu^{2,7,12,16**}

* Chun-Chi Yang and Chung-Feng Huang contributed equally.

** Chi-Yi Chen and Ming-Lung Yu contributed equally.

¹Division of Gastroenterology and Hepatology, Department of Internal Medicine, Chi Mei Medical Center, Yongkang District, Tainan, Taiwan.

²Hepatobiliary Division, Department of Internal Medicine and Hepatitis Center, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.

³Ph.D. Program in Translational Medicine, College of Medicine, Kaohsiung Medical University, Academia Sinica, Kaohsiung, Taiwan.

⁴Division of Hepatogastroenterology, Department of Internal Medicine, ChiaYi Chang Gung Memorial Hospital, Chiayi, Taiwan.

⁵College of Medicine, Chang Gung University, Taoyuan, Taiwan.

⁶Division of Gastroenterology, Department of Internal Medicine, St. Martin De Porres Hospital, Chiayi, Taiwan.

⁷Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.

⁸Division of Gastroenterology, Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan.

⁹Division of Hepatology and Gastroenterology, Department of Internal Medicine, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.

¹⁰School of Medicine, Fu-Jen Catholic University, New Taipei City, Taiwan.

¹¹Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

¹² Hepatitis Research Center, College of Medicine; Center for Liquid Biopsy and Cohort Research, Kaohsiung Medical University, Kaohsiung, Taiwan.

¹³Center for Digestive Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.

¹⁴School of Medicine, China Medical University, Taichung, Taiwan.

¹⁵Division of Infectious Diseases, Department of Internal Medicine, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan.

¹⁶School of Medicine and Doctoral Program of Clinical and Experimental Medicine, College of Medicine and Center of Excellence for Metabolic Associated Fatty Liver Disease, National Sun Yat-sen University, Kaohsiung, Taiwan.

¹⁷Division of Gastroenterology, Department of Internal Medicine, Taitung Mackay Memorial Hospital, Taitung, Taiwan.

¹⁸Mackay Medical College, New Taipei City, Taiwan.

¹⁹Liver Research Unit, Department of Hepato-Gastroenterology and Community Medicine Research Center, Chang Gung Memorial Hospital at Keelung, College of Medicine, Chang Gung University, Keelung, Taiwan.

²⁰Department of Gastroenterology, Division of Internal Medicine, Show Chwan Memorial Hospital, Changhua, Taiwan.

²¹Division of Gastroenterology, Department of Internal Medicine, Yuan's General Hospital, Kaohsiung, Taiwan.

²²Division of Gastroenterology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.

²³Division of Gastroenterology and Hepatology, Far Eastern Memorial Hospital, New Taipei City, Taiwan.

²⁴Division of Gastroenterology and Hepatology, Department of Internal Medicine, Chi Mei Medical Center, Liouying, Tainan, Taiwan.

²⁵Wen-Chih Wu Clinic, Fengshan, Kaohsiung, Taiwan.

²⁶Department of Gastroenterology, Renai Branch, Taipei City Hospital, Taipei, Taiwan. ²⁷Department of Gastroenterology and Hepatology, Changhua Christian Hospital, Changhua, Taiwan.

²⁸Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.

²⁹Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and School of Medicine, Tzu Chi University, Taipei, Taiwan.

³⁰Liver Center, Cathay General Hospital, Taipei, Taiwan.

³¹Division of Gastroenterology, Tainan Municipal Hospital (Managed By Show Chwan Medical Care Corporation), Tainan, Taiwan.

³²Division of Gastroenterology, Department of Internal Medicine Tri-Service General Hospital Penghu Branch, National Defense Medical Center, Taipei, Taiwan. ³³Healthcare and Service Center, Taipei Veterans General Hospital, Taipei, Taiwan; Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.

³⁴Institute of Clinical Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.

³⁵Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan.

³⁶Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.

³⁷Yang Ming Hospital, Chiayi, Taiwan.

³⁸Penghu Hospital, Ministry of Health and Welfare, Penghu, Taiwan.

³⁹National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan.

⁴⁰Division of Gastroenterology and Hepatology, Department of Internal Medicine, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan

⁴¹School of Medicine for International Students, College of Medicine, I-Shou University, Kaohsiung, Taiwan

⁴²Hepatitis Research Center and Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.

⁴³Institute of Clinical Medicine, National Yang-Ming Chiao Tung University, Taipei, Taiwan.

⁴⁴ School of Medicine, Tzuchi University, Hualien, Taiwan.

⁴⁵Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan.

⁴⁶Division of Gastroenterology and Hepatology, Department of Medicine, Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi, Taiwan.

Correspondence:

Ming-Lung Yu

Hepatobiliary Division, Department of Internal Medicine and Hepatitis Center, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.

No. 100, Tzyou 1st Road, Kaohsiung, Taiwan

Email: fish6069@gmail.com

OR

Chi-Yi Chen

Division of Gastroenterology and Hepatology, Department of Medicine, Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi, Taiwan.

Supplementary Table 1. Factors associated with SVR12

Predictor	SVR12 n/N (%)	Unadjusted OR (95% CI)	P-value	Adjusted OR (95% CI)	P-value
Age					
<65 years	4,803/4,870 (98.6)	1		1	
≥65 years	2,319/2,334 (99.4)	2.16 (1.23-3.78)	0.01	1.57 (0.86-2.84)	0.14
Gender					
Female	3,370/3,397 (99.2)	1.83 (1.15-2.91)	0.01	1.31 (0.81-2.13)	0.28
Male	3,752/3,807 (98.6)	1		1	
Liver cirrhosis					
No	6,780/6,856 (98.9)	1.57 (0.68-3.62)	0.29		
Yes	342/348 (98.3)	1			
HCV genotype					
GT3	272/286 (95.1)	1		1	
Non-GT3	6,850/6,918 (99.0)	5.18 (2.88-9.33)	<0.01	4.31 (2.33-7.96)	<0.01
HCV RNA					
≥6,000,000 IU/mL	1,388/1,418 (97.9)	1		1	
<6,000,000 IU/mL	5,729/5,779 (99.1)	2.48 (1.57-3.91)	<0.01	2.27 (1.42-3.61)	<0.01
HIV					
No	6,874/6,946 (99.0)	3.85 (1.96-7.55)	<0.01	2.45 (1.21-4.98)	0.01
Yes	248/258 (96.1)	1		1	

Drug adherence					
≥ 80%	7,107/7,186 (98.9)	17.99 (5.11-63.38)	<0.01	25.45 (6.70-96.63)	<0.01
< 80%	15/18 (83.3)	1		1	

Note: SVR: sustained virological response. SVR12: undetectable HCV RNA throughout 12 weeks of post-treatment follow-up period. GT: genotype. HIV: human immunodeficiency virus. OR: odds ratio. CI: confidence interval.

Supplementary table 2. Laboratory changes between baseline and SVR12 in SVR patients with chronic kidney disease

	Chronic kidney disease (n=1,506)*			Baseline eGFR ≤ 60 ml/min/1.73m ² (n=1,320)			Baseline eGFR > 60 ml/min/1.73m ² (n=186)		
	Baseline	SVR12	P value ^a	Baseline	SVR12	P value ^a	Baseline	SVR12	P value ^a
AST, U/L	42.11±37.83	22.80±14.93	<0.01*	40.95±37.85	22.35±14.72	<0.01*	50.58±36.92	25.99±16.07	<0.01*
ALT, U/L	46.82±53.12	18.16±21.75	<0.01*	44.87±52.58	17.62±22.30	<0.01*	60.96±55.14	22.00±17.07	<0.01*
Total bilirubin, mg/dL	0.63±0.40	0.62±0.31	0.15	0.60±0.31	0.59±0.30	0.59	0.85±0.75	0.77±0.33	0.13
INR, sec	1.03±0.45	1.00±0.11	0.04*	1.03±0.48	1.00±0.11	0.06	1.02±0.09	1.01±0.10	<0.01*
Albumin, g/dL	4.08±0.45	4.16±0.42	<0.01*	4.05±0.44	4.13±0.42	<0.01*	4.29±0.42	4.38±0.38	<0.01*
Platelet, x10 ³ U/L	195.81±70.54	197.64±65.82	0.10	192.64±68.62	194.80±64.18	0.15	211.40±76.47	214.63±73.11	<0.01*
FIB-4	2.53±2.10	2.21±1.59	<0.01*	2.59±2.18	2.25±1.55	<0.01*	2.32±1.81	1.95±1.79	0.01*
Creatinine, mg/dL ^b	2.05±1.98	2.09±2.10	0.20	2.31±2.10	2.36±2.23	0.27	0.87±0.19	0.90±0.33	0.19
eGFR,ml/min/1.73m ^{2b}	48.30±26.01	50.58±28.26	<0.01*	39.25±16.57	42.23±22.01	<0.01*	88.90±21.53	87.83±22.39	0.35

Note: Values expressed as mean ± standard deviation or sample size and proportion (%). *excluded Hemodialysis (n=492). AST, aspartate aminotransferase; ALT, alanine aminotransferase; INR, international normalized ratio; FIB-4, fibrosis-4 index; eGFR, estimated glomerular filtration rate. SVR: sustained virological response. SVR12: undetectable HCV RNA throughout 12 weeks of post-treatment follow-up period.